Natera (NTRA) Stock Price, News & Analysis

Company Overview

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection. The company also provides genetic counseling and supports clinical use through validation studies and peer-reviewed publications.

Natera operates certified clinical laboratories and serves healthcare providers, hospitals, fertility clinics, and biopharmaceutical partners in the United States and in international markets. The company engages in collaborations with clinicians and drug developers to support clinical trials, companion diagnostic development, and translational research. Its offerings are positioned to support both clinical decision-making and research applications across multiple therapeutic areas.

Founded in the mid-2000s and headquartered in the San Francisco Bay Area, Natera is a publicly traded company listed on the Nasdaq. The business emphasizes ongoing research and product development, regulatory compliance, and scientific validation to expand the clinical utility of its genetic testing platforms. Its leadership and scientific teams comprise professionals with experience in genomics, diagnostics, and laboratory medicine.

Key Stats

• Today's Range: $227.93 to $237.15
• 50-Day Range: $186.36 to $231.41
• 52-Week Range: $131.81 to $256.36
• Volume: 2.63 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: $33.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $256.53
• Consensus Rating: Moderate Buy

Natera Stock Analysis - MarketRank™

Natera scored higher than 69% of companies evaluated by MarketBeat, and ranked 221st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Natera has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 2 strong buy ratings, 14 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Natera has a consensus price target of $256.53, representing about 10.9% upside from its current price of $231.41.

Amount of Analyst Coverage

Natera has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Natera are expected to grow in the coming year, from ($1.50) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Natera is -141.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Natera is -141.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Natera has a P/B Ratio of 18.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.66% of the float of Natera has been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Natera has recently decreased by 4.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natera does not currently pay a dividend.

Dividend Growth

Natera does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.02

News Sentiment

Natera has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Natera this week, compared to 10 articles on an average week.

Search Interest

Only 6 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

MarketBeat Follows

14 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,283,396.00 in company stock.

Percentage Held by Insiders

5.05% of the stock of Natera is held by insiders.

Percentage Held by Institutions

99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 6/20/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:NTRA
• CIK: 1604821
• Web: www.natera.com
• Phone: (650) 249-9090
• Fax: N/A
• Employees: 6,140
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Natera: $256.53
• High Price Target: $300.00
• Low Price Target: $172.00
• Potential Upside/Downside: +10.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$208.16 million
• Net Margins: -9.05%
• Pretax Margin: -11.44%
• Return on Equity: -14.74%
• Return on Assets: -10.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.96
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: $2.31 billion
• Price / Sales: 14.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.38 per share
• Price / Book: 18.69

Miscellaneous

• Outstanding Shares: 143,210,000
• Free Float: 135,983,000
• Market Cap: $33.14 billion
• Optionable: Optionable
• Beta: 1.56